Effects and Risks Associated with Novel Psychoactive Substances
Mislabeling and Sale as Bath Salts, Spice, and Research Chemicals

Nicolas Hohmann, Gerd Mikus, David Czock

SUMMARY

Background: The number of newly reported psychoactive substances in Europe is now higher than ever. In order to evade legal restrictions, old and novel psychoactive substances from medical research and their derivatives are commonly mislabeled as “not for human consumption” and offered for sale on the Internet and elsewhere. Such substances are widely taken by young people as “club drugs.” Their consumption must be considered in the differential diagnosis of psychiatric, neurological, cardiovascular, or metabolic disturbances of unclear origin in a young patient.

Methods: Selective review of pertinent literature retrieved by a PubMed search, including publications by government-sponsored organizations.

Results: From 2010 to 2012, 163 substances were reported to the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), mostly either synthetic cannabinoids (39.3%) or synthetic cathinones (16.6%). Synthetic cannabinoids alter mood and perception; intoxications cause agitation, tachycardia, and arterial hypertension. Synthetic cathinones are hallucinogenic stimulants with predominantly cardiovascular and psychiatric side effects. Severe intoxications cause serotonin syndrome and potentially fatal rhabdomyolysis. Substances in either of these classes often escape detection in screening tests.

Conclusion: Young persons who present with agitation and cardiovascular and/or psychiatric manifestations of unclear origin and whose drug screening tests are negative may be suffering from an intoxication with a novel psychoactive substance. Physicians should know the classes of such substances and their effects. Targeted toxicological analysis can be carried out in a toxicology laboratory or a facility for forensic medicine.

Cite this as:
not cross-react with the THC test, and synthetic cathinones are not detected by the ELISA-based amphetamine test. Some NPS do, however, cross-react with tests for methamphetamine. Piperazine gives mixed results on the amphetamine test (e3). NPS are generally detected by other means, mainly by specific gas-chromatographic mass spectrometry (GC-MS) and liquid-chromatographic tandem mass spectrometry (LC-MS/MS). Thus, targeted analysis can be carried out in a toxicology laboratory or a forensic medical facility (e3–e5).

For many types of NPS, our current knowledge base is incomplete. Their study is fraught with methodological difficulties; in particular, controlled clinical trials are hard to carry out and only very few have actually been performed. Most of the available data are derived from retro- or prospectively analyzed case series of intoxication and from interviews with drug users, and are thus of limited scientific value. The attribution of particular manifestations to particular substances is often difficult because unidentified substances may be consumed and multiple substances may be taken at once.

### The consumption of novel psychoactive substances in Germany

In the MoSyD (Monitoring System for Drug Trends) study, data on the consumption of NPS were collected in Frankfurt am Main, Germany. In 2012, the lifetime prevalence of “spice” consumption stabilized at 7% for persons aged 15 to 18, with a 30-day prevalence of 2% (4). 16% stated that they knew someone who consumed “herbal incense” (4). For other types of NPS, such as “bath salts,” the lifetime

---

**TABLE 1**

Cannabinones, cathinones, and phenylethylamines listed in the appendices to the German Narcotics Act (BtMG)

<table>
<thead>
<tr>
<th>BtMG appendix</th>
<th>Appendix I (narcotics that must not be sold*1)</th>
<th>Appendix II (narcotics that may be sold but not prescribed*2)</th>
<th>Appendix III (narcotics that may be sold and prescribed*3)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Substance class</td>
<td>(synthetic) cathinones</td>
<td>(synthetic) cannabinoids</td>
<td>Piperazine derivatives</td>
</tr>
<tr>
<td>New phenylethylamines/ephedrine (methylcathinone)</td>
<td>methamphetamine (4-FA, 4-FMP) dimethoxyamphetamine (DMMA)</td>
<td>methedrone (4-fluoromethcathinone, 4-FMC) methyleneoxypropylacroleine (MDPV) 4-methylcathinone (4-MEC) naphrylone (naphthylpyrovalerone) pyrovalerone butylone methylene (3,4-methyleneoxy-N-methcathinone, MDMC) buphedrone 3,4-dimethylethcathinone (3,4-DMMC) 3-fluoromethcathinone (3-FMC) pentedrone alpha-PVP (alpha-pyrrolidinovalerophenone) 4-methylamphetamine 4-fluoromethcathinone (4-FMA) p-methoxyethylamphetamine (PMEA) 5-APB, 6-APB ethylphenidate</td>
<td>AM-694, AM-1220, AM-1220 A azapen derivative, AM-2201, AM-2232, AM-2233 CP47, 497 CP47, 497-C6-homologue CP47, 497-C8-homologue CP47, 497-C9-homologue JWH-007, -015, -018, -019, -073, -081, -122, -200, -203, -210, -250, -251, -307, 5-fluoropentyl-JWH-122 RCS-4, RCS-4 ortho-isomer (o-RCS-4) delta-9-THC 1-adamantyl(1-pentyl-1H-indole-3-yl)methanone AKB-48, AKB-48F UR-144 and 5-fluoro-UR-144</td>
</tr>
</tbody>
</table>

*1 Sale and prescription forbidden. Special permission for scientific purposes can be obtained from the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM).
*2 Sale permitted, prescription forbidden.
*3 Prescription allowed under the provisions of the Narcotics Prescription Ordinance (Betäubungsmittel-Verschreibungsverordnung, BtMVV).

Up to date as of the 26th and 27th amendments to the Narcotics Act, which went into effect on 26 July 2012 and 17 July 2013, respectively.
prevalence of consumption was found to be 2%, and the 30-day prevalence 1% (4). A number of reports appeared in 2012 about the consumption of “research chemicals” in the party scene and among marginalized youth (4).

Hermanns-Clausen et al. analyzed a series of 50 patients who were seen in an emergency room and reported to the Freiburg Emergency Poison Control Center because of suspected synthetic cannabinoid intoxication, from September 2008 to April 2011 (5).

Moreover, publications from Germany include a case series of persons driving under the influence of synthetic cannabinoids and a case report of withdrawal manifestations and dependency after the consumption of “spice gold” (6, 7).

The actual percentage of users that develop side effects may be underestimated in such studies. A direct comparison of current figures on the prevalence of substance consumption among adolescents with the reports from Germany leads us to suspect that NPS are, in fact, used much more commonly than the statistics reveal. The reasons for this probably include

- a lack of information,
- inadequate means of detection,
- only rare confirmation by laboratory testing in patients with clinical findings of unclear origin,
- and/or the rarity of intoxication compared to consumption.

A learning effect may also be present: once hospital emergency room staff have sufficient personal experience with NPS intoxications, they are less likely to call the Poison Control Center to ask for help with management.

Objectives
In this review, we discuss the pharmacology and clinical effects of the more common classes of NPS in the light of pertinent information from scientific reports and from publications of government-sponsored organizations.

Methods
A selective keyword search was carried out in the PubMed database (Table 2). All abstracts were read and publications with information on the pharmacology, epidemiology, or clinical manifestations of NPS were selected for analysis. The references of these publications were also examined for important sources not revealed by the search. 63 publications were considered informative enough for use in the preparation of this review (Table 2).

Synthetic cathinones (“bath salts”)
Synthetic cathinone derivatives are β-keto-α-methyl-phenylalkylamines (β-keto-α-methyl-phenylalkylamines) that are chemically related to methamphetamine (“crystal meth”) and 3,4-methylenedioxymethamphetamine (“ecstasy”) (Figure 1) (8). Cathinone is found naturally in the khat plant (Catha edulis), which is chewed in Yemen for its stimulant effect (e6). Cathinone derivatives were used as antidepressants in the Soviet Union in the 1930s (9). Methamphetamine was given extensively to German soldiers in the Second World War, under the trade name Pervitin, to counteract fatigue. Pyrovalerone was tested in France and the USA in 1970 for use as a stimulant in patients with chronic fatigue; investigation revealed marked CNS stimulation and accentuation of the subjective need for movement (e7). Synthetic cathinones, particularly mephedrone, are now commonly sold with intentional mislabeling as “bath salts.” They come in the form of white, beige, or brown crystals (10). They are apparently synthesized and packaged in China and/or India for the European market (e8). In an online poll of British clubbers, carried out in 2009, 43% said they
had used mephedrone at least once (11). In the USA, consumption figures and the number of calls to Poison Control Centers rose from 2009 to 2011, but began to drop again in 2012 (12, 13). Among twelfth-graders in the USA, the 1-year prevalence of synthetic cathinone consumption was 1.3% in 2012 (e9); the prevalence of consumption of “legal high products” in Germany is similar (2%) (4). The substances most commonly detected in cases of cathinone intoxication are MDPV, pyrovalerone, methylone, pentylone, and alpha-PVP (14).

“Bath salts” are rapidly absorbed: the “high” is at its most intense 1.5 hours after oral consumption and lasts for 2–8 hours, depending on the substance (15, 16). Synthetic cathinones are potent inhibitors of the serotonin reuptake transporter (SERT) as well as the reuptake transporters for dopamine (DAT) and norepinephrine (NAT) (e10). Selectivity varies from one substance to another (e10). These substances can be classified in three groups (e11):

- cocaine-MDMA mixed type (mephedrone, methylone, ethylone, butylone, and naphyrone): nonspecific monoamine reuptake inhibition with about five times more DAT than SERT inhibition. All except naphyrone also promote serotonin release. Mephedrone promotes dopamine release.
- methamphetamine-like type (cathinone, flephedrone, and methcathinone): these substances inhibit dopamine and norepinephrine reuptake and promote dopamine release.
- pyrovalerone type (pyrovalerone, MDPV): selective inhibition of catecholamine reuptake. Does not promote the release of monoamines.

Flephedrone, mephedrone, and methcathinone are also 5HT₂A agonists. The blood–brain barrier is highly permeable to mephedrone and MDPV in particular (e10). These substances are metabolized through the activity of cytochrome P450 isoenzymes or catechol-O-methyltransferase and are excreted either by the kidneys or by the biliary system (e4).
The psychotic manifestations of synthetic cathinone use often consist of paranoia with auditory and visual hallucinations (23), which can persist for up to four weeks and take a more severe course than with other amphetamines (23, 24). In most cases of intoxication with psychotic symptoms, MDPV is the cause (13). Intoxication can manifest itself clinically with sympathomimetic effects, delirium, or the serotonin syndrome. The patients develop aggressiveness, psychotic manifestations, fever up to 41.5 °C, and/or arterial hypertension (21, 24), and they may have metabolic acidosis, an elevated creatine kinase (CK) level, and muscle damage ranging to rhabdomyolysis (21, 24). The simultaneous appearance of hyperthermia and rhabdomyolysis in MDMA intoxication has been reported and attributed to decoupling of oxidative phosphorylation (e13). In very severe cases, disseminated intravascular coagulation (DIC) can arise, leading to potentially fatal multi-organ failure. From September 2009 to October 2011, there were 128 documented deaths associated with mephedrone use in the United Kingdom: of the 62 cases that could be

**Box 1**

### Adverse effects of, and signs of intoxication with, synthetic cathinones*

#### cardiovascular
- tachycardia (22–56%)
- arterial hypertension (4–25%)
- palpitations (11–28%)
- chest pain (6–28%)
- dyspnea (8–11%)
- vasoconstriction (6–8%)
- ECG changes (2%)
- arrhythmia
- myocardial infarction
- mycarditis
- ST-segment changes
- syncope

#### psychiatric
- agitation (50–82%)
- aggression (57%)
- hallucinations (27–40%)
- confusion (14–34%)
- anxiety (15–17%)
- insomnia (4%)
- catatonia (1%)
- anhedonia
- anorexia
- depression
- increased libido
- injurious behavior
- panic attacks
- self-injurious behavior
- suicidality
- psychosis

#### pulmonary
- hyperventilation/tachypnea (7%)
- dyspnea (8–11%)

#### muscular
- CK elevation (3–20%)
- rhabdomyolysis (6%)
- compartment syndrome

#### cutaneous
- rash (6–7%)

#### other
- fever (9–11%)
- abnormal liver function tests (2%)
- abscesses, bruxism
- diaphoresis
- disseminated intravascular coagulation (DIC)
- hyperthermia
- urinary disturbances
- necrotizing fasciitis
- spontaneous subcutaneous emphysema
- unpleasant body odor (mephedrone)
- soft-tissue injury

#### metabolic
- hyponatremia
- hypokalemia (4%)
- acidosis (1%)

#### gastrointestinal
- nausea/vomiting (5–22%)
- abdominal pain (2–5%)

#### renal
- elevated creatinine level (1–5%)
- acute renal failure

#### neurological
- headache (5–17%)
- mydriasis (7–13%)
- light-headedness (8–12%)
- paresthesia (4%)
- seizures (2–4%)
- dystonic movements (2%)
- tremor (2%)
- amnesia
- dysgeusia
- cerebral edema
- motor automatisms
- muscle spasm
- nystagmus
- parkinsonism
- stroke

#### gastrointestinal
- nausea/vomiting (5–22%)
- abdominal pain (2–5%)

#### cutaneous
- rash (6–7%)

#### other
- fever (9–11%)
- abnormal liver function tests (2%)
- abscesses, bruxism
- diaphoresis
- disseminated intravascular coagulation (DIC)
- hyperthermia
- urinary disturbances
- necrotizing fasciitis
- spontaneous subcutaneous emphysema
- unpleasant body odor (mephedrone)
- soft-tissue injury

*modified from (13, 16, 19, 20, e12)
assessed further, death was due to the acute toxicity of the drug itself in 26, and to self-destructive or suicidal behavior in 18 (25). In case reports of deaths in 2011 and 2012, other synthetic cathinones play a larger role, such as MDPV, butylone, and methedrone (e11).

**Synthetic cannabinoids (“spice”)**

“Spice” appeared in Europe in 2005, accompanied by the claim that its psychotropic effect was induced purely by natural, botanical components (26). The real active substance was discovered in 2009 with the detection of undeclared synthetic cannabinoid receptor (CB) agonists by Volker Auwärter and colleagues at the University of Freiburg (Germany) (27).

CB agonists are classified according to their chemical structure, as follows (28) (Figure 2):

- **classic cannabinoids**, such as delta-9-tetrahydrocannabinol (THC) from the cannabis plant (*Cannabis sativa*), the approved anti-emetic nabilone, and HU cannabinoids, which closely resemble THC.
- **non-classic cannabinoids**, such as the cyclohexylphenol (CP) cannabinoids.
- **aminoalkylindoles**: the JWH series, synthesized by the chemist J. W. Huffmann, contains many CB ligands.
- **eicosanoids**, such as the endocannabinoid anandamide.

These substances are sold as “herbal incense” supposedly derived from plants, and the consumers smoke them. The synthetic cannabinoids are sprayed onto pharmacologically inactive vegetable matter accounting for most of the bulk of “spice” by weight. The ingredients listed on the package are generally incomplete or false. One gram of “spice” contains 77.5 to 202 mg of synthetic cannabinoid, with high variability from one package to another (29, 30). Consumers do not know what active substance they are using, or in what dose. Further ingredients include the β₂-mimetic substance clenbuterol, which may be responsible for the sympathomimetic manifestations of “spice” intoxication (tachycardia, hypokalemia), and large amounts of tocopherol (vitamin E), possibly added in order to prevent detection (27).

Research on the cannabinoid system has revealed several hundred agonists that might be abused, with varying affinity for the CB₁ and CB₂ receptors (3). The endocannabinoid system participates in the regulation of physiological processes such as caloric balance and the control of arterial smooth muscle tone (e14, e15). CB₁ receptors are found mainly in the nervous system and CB₂ receptors mainly in the spleen, the tonsils, and cells of the immune system, as well as on particular types of neurons (28). Synthetic cannabinoids are potent CB₁ agonists: the affinity of JWH018 for the CB₁ receptor is five times as high as that of THC, while that of AM-694 is 500 times as high (e16, e17). Users report that “spice” has a stronger psychotropic effect than marijuana (31).

Synthetic cannabinoids exert a THC-like effect, with alterations of mood, perception, sleep and wakefulness, body temperature, and cardiovascular function (5). Their side effects are more varied and more severe than those of THC, with the more common ones being...
tachycardia, arterial hypertension, hyperglycemia, hypokalemia, hallucinations, and agitation (Box 2) (5, 28, e18, e19). Chest pain, myocardial ischemia, and psychosis are rarer (7, 32). As the “spice” sold at any particular time may contain new cannabinoids, previously unrecognized side effects may arise. In the USA, for example, widespread use of the fluoridated synthetic cannabinoid XLR-11 was associated with a series of cases of acute renal failure in young users in late 2012 (26). Synthetic cannabinoids can cause dependency (7, 32). Very few deaths attributable to the consumption of synthetic cannabinoids have been reported to date: there has been one case of fatal coronary ischemia, as well as one of suicide in a user who became depressed after consuming a cannabinoid substance (3).

Other NPS (“research chemicals”)

**Piperazine derivatives**

Piperazine is an anthelminthic drug that is structurally related to various other classes of drugs, including antidepressants (e.g., trazodone), atypical neuroleptic drugs (e.g., olanzapine), and antihistamines (e.g., cetirizine). Psychoactive piperazine derivatives such as 1-benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) have been drugs of abuse since about the year 2000 (33). They are often taken orally in multi-substance combinations. Piperazine derivatives stimulate the release of dopamine, norepinephrine, and serotonin and inhibit monoamine reuptake (34). Exceptionally for psychoactive substances, BZP and TFMPP have been studied in controlled trials. The manifestations of intoxication are typical for stimulants (eTable 1). A study of the effects of combined BZB, TFMPP, and alcohol consumption was terminated because of serious adverse effects—arterial hypertension, tachycardia, agitation, anxiety, hallucinations, vomiting, insomnia, and migraine (35). The manifestations depend on the plasma concentration of the drug: concentrations between 0 and 0.5 mg/L are associated with anxiety, vomiting, and palpitations, concentrations above 0.5 mg/L with agitation and confusion. Seizures may occur with plasma concentrations as low as 0.05 mg/L but regularly accompany concentrations above 2.15 mg/L (36).

**Aminoindanes**

MDAI (5,6-methylenedioxy-2-aminoindane), 5-IAI (5-iodo-2-aminoindane), and MMAI (5-methoxy-6-methyl-2-aminoindane) have a so-called entactogenic effect (i.e., they intensify the perception of one’s own emotions) and are therefore marketed as “legal” alternatives to MDMA (37). These drugs are weak inhibitors of monoamine reuptake, but they powerfully stimulate the release of non-vesicular serotonin. 5-IAI and MDAI became more widespread around the time that mephedrone was...
forbidden. Its desired effects are mild euphoria, distorted spatial and temporal perception, intense color perception, and the sense that one has a better understanding of other persons’ emotions. The effect commences as soon as 10 minutes after oral consumption of the drug, lasts an hour, and then comes gradually to an end. The undesired effects are of a cardiovascular, neurological, or psychiatric nature. The scientific literature contains very little information about the potential toxicity of 2-aminoindane derivatives. In animal studies, a dose 40 times higher than a behavior-changing dose had no toxic effects (including neurotoxic ones). Yet these are by no means harmless substances: among human users, there have been reported cases of hyperthermia, serotonin syndrome, rhabdomyolysis, and death (37, 38, e20).

“Bromo-dragonfly”

“Bromo-dragonfly” ([R]-[4-bromofuro(2,3-f)[1]benzofuran-8-yl]propane-2-amine) is a substituted phenylethylamine with a similar hallucinogenic effect to that of LSD (39). It is a potent agonist of 5-HT1, 5-HT2A, and α1 receptors. Its latency of effect is up to six hours; the effect (visual and auditory hallucinations, a feeling of well-being and solidarity) can last as long as three days (39). The amount of active substance varies markedly from one batch to another, so that reliable dosing is impossible and there is a danger of overdose (e21). “Bromo-dragonfly” is highly toxic: it can cause seizures, acidosis, pulmonary edema, and prolonged vasospasm leading to gangrene and multiple organ failure (39, 40). Deaths have been reported, and there has also been a reported case of uncontrollable vasospasm despite maximal vasodilatory treatment, leading to the amputation of multiple fingers (39, 40).

Overview

Today’s psychoactive substance users can choose among various stimulants, hallucinogens, and sedatives with a mouse-click (eTable 1). Some of these substances are prohibited by the German Narcotics Act, but many are too new to be covered by it. The substances in circulation change frequently, but their effects and toxicities tend to remain the same; different groups of substances have typical profiles (eTable 1), which, however, overlap. Stimulants, in particular, can cause sympathomimetic manifestations or a serotonin syndrome. If standard drug screening is negative in such a situation, an intoxication with a new psychotropic substance should be suspected. The diagnosis can be established by analysis in a specialized laboratory, e.g., a toxicology laboratory or a forensic medical facility.

Conflict of interest statement

The authors state that no conflict of interests exists.

Manuscript received on 30 August 2013, revised version accepted on 16 December 2013.

Translated from the original German by Ethan Taub, M.D.

KEY MESSAGES

- 163 novel psychoactive substances of abuse were reported to the European Monitoring Centre for Drugs and Drug Addiction in the period 2010–2012.
- These substances belong to the chemical groups of synthetic cannabinoids, synthetic cathinones, phenylethylamines, tryptamines, and piperazines and are often undetectable by standard drug screening tests.
- Synthetic cannabinoids are CB1 receptor agonists. Compared to THC, they are more potent and longer-acting and have much worse adverse effects.
- Synthetic cathinones are bk-aminetamines with both stimulant and hallucinogenic effects. They may cause severe intoxication.
- Young persons who present with psychiatric, metabolic, and/or cardiovascular manifestations of unclear origin and whose drug screening tests are negative may be suffering from an intoxication with a novel psychoactive substance.

REFERENCES

38. For eReferences please refer to: www.aerzteblatt-international.de/14m0139
39. For SDT-References please refer to: www.aerzteblatt-international.de/ref0914

Corresponding author
PD Dr. med. David Czock
Medizinische Klinik (Krehl-Klinik)
Abt. Klinische Pharmakologie und Pharmakoepidemiologie
Im Neuenheimer Feld 410 D-69120 Heidelberg, Germany
david.czock @med.uni-heidelberg.de
Effects and Risks Associated with Novel Psychoactive Substances

Mislabeling and Sale as Bath Salts, spice, and Research Chemicals

Nicolas Hohmann, Gerd Mikus, David Czock

eREFERENCES

# Summary of characteristics of novel psychoactive substances

<table>
<thead>
<tr>
<th>Synthetic cathinones</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Substances</strong></td>
<td>mephedrone, methylone, ethylone, butylone, naphyrone, methcathinone, flephedrone, MDPV, α-PVP, pyrovalerone, etc.</td>
</tr>
<tr>
<td><strong>Colloquial names</strong></td>
<td>bath salts, meow meow (mephedrone), ivory wave, vanilla sky, cloud 9, lunar wave, others</td>
</tr>
<tr>
<td><strong>Usual dose</strong></td>
<td>5–20 mg</td>
</tr>
<tr>
<td><strong>Mechanism of action</strong></td>
<td>monoamine reuptake inhibitors (DAT, NAT, SERT), dopamine-serotonin receptor agonists, serotonin/dopamine release by DAT and SERT</td>
</tr>
<tr>
<td><strong>Effects</strong></td>
<td>euphoria, excitement, intensified perception of music, brightening of mood, reduction of hostility, clear thinking, mild sexual stimulation</td>
</tr>
<tr>
<td><strong>Side effects</strong></td>
<td>cardiovascular: tachycardia, hypertension, vasoconstriction, hyperthermia; neurological: mydriasis; psychiatric: hallucinations, anorexia, depression, insomnia, craving, anxiety, panic attacks</td>
</tr>
<tr>
<td><strong>Intoxication</strong></td>
<td>cardiovascular: myocardial infarction, circulatory failure; neurological: seizures, cerebral edema, stroke; psychiatric: hallucinations, anorexia, depression, insomnia, craving, anxiety, panic attacks</td>
</tr>
</tbody>
</table>

Sources: 15–25, e10–e12

<table>
<thead>
<tr>
<th>Synthetic cannabinoids</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Colloquial names</strong></td>
<td>spice K2, K2-blonde, spice diamond, spice gold, arctic spice, genie, zombie 2010, black box, smoke’n’skulls, others</td>
</tr>
<tr>
<td><strong>Usual dose</strong></td>
<td>1 package (usually 3 g) = 8 joints</td>
</tr>
<tr>
<td><strong>Mechanism of action</strong></td>
<td>CB₁ receptor agonist</td>
</tr>
<tr>
<td><strong>Effects</strong></td>
<td>increased empathy, feeling of well-being, euphoria, disinhibition, loquacity, hunger</td>
</tr>
<tr>
<td><strong>Side effects</strong></td>
<td>cardiovascular: tachycardia, hypertension; neurological: dizziness, mydriasis; psychiatric: agitation, hallucinations; other: nausea/vomiting, hypokalemia, hyperglycemia</td>
</tr>
<tr>
<td><strong>Intoxication</strong></td>
<td>psychosis, seizures, sympathomimetic effects</td>
</tr>
</tbody>
</table>

Sources: 3, 5, 7, 26–32, e16–e19

<table>
<thead>
<tr>
<th>Piperazine derivates</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Substances</strong></td>
<td>benzylpiperazine (BZP), trifluoromethylphenylpiperazine (TFMPP), etc.</td>
</tr>
<tr>
<td><strong>Colloquial names</strong></td>
<td>nemesis, jax, A2, Benny Bear, flying angel, legal E or legal X, pep X, others</td>
</tr>
<tr>
<td><strong>Usual dose</strong></td>
<td>300 mg BZP, 75 mg TFMPP</td>
</tr>
<tr>
<td><strong>Mechanism of action</strong></td>
<td>sympathomimetic stimulation; BZP, dopaminergic and noradrenergic; TFMPP, serotoninergic</td>
</tr>
<tr>
<td><strong>Effects</strong></td>
<td>increased self-confidence, euphoria, intensified emotion</td>
</tr>
<tr>
<td><strong>Side effects</strong></td>
<td>cardiovascular: palpitations, tachycardia, arterial hypertension; neurological: migraine; psychiatric: agitation, anxiety, hallucinations, vomiting, insomnia, dysphoria; other: diminished appetite</td>
</tr>
<tr>
<td><strong>Intoxication</strong></td>
<td>cardiovascular: tachycardia, hypertension, QT prolongation; abdominal: nausea, epigastric pain; neurological: headache, tremor; psychiatric: confusion, insomnia, intrusive thoughts, mood swings, irritability; other: sympathomimetic effects</td>
</tr>
</tbody>
</table>

Sources: 15–25, e10–e12
### Phenylethylamines

<table>
<thead>
<tr>
<th>Substances</th>
<th>Colloquial names</th>
<th>Usual dose</th>
<th>Mechanism of action</th>
<th>Effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>aminoindanines: 5-iodo-2-aminoindane (5-IAI); 5-methoxy-6-methyl-2-aminoindane (MMAI); 5,6-methylenedioxy-2-aminoindane (MDAI)</td>
<td>woof woof, sparkle, mindy, others</td>
<td>70–300 mg MDAI</td>
<td>MDMA analogue, monoamine reuptake inhibitor, promotes 5HT release</td>
<td>hallucinations, psychomotor activation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>cardiovascular: tachycardia, hypertension, arterial hypotension</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>neurological: allodynia, hypalgesia, dizziness, nystagmus, mydriasis,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>increased muscle tone</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>other: hyperthermia, worsened vision and hearing, hyperventilation, vomiting</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Intoxication nervous system: seizures, rhabdomyolysis, sympathetic effects, serotonin syndrome</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Side effects neurological: seizures</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>pulmonary: respiratory problems</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>cardiovascular: vasospasm</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>other: multi-organ failure, gangrene</td>
</tr>
</tbody>
</table>

**Sources:** 33–36, e22

### Substances

<table>
<thead>
<tr>
<th>1-(8-bromobenzo[1,2-b;4,5-b']difuran-4-yl)-2-aminopropane</th>
<th>bromo-dragonfly</th>
<th>200–800 µg</th>
<th>5HT₁-, 5HT₂-, and α₁-agonist</th>
<th>potent, long-acting hallucinogen</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Side effects neurological: seizures</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>pulmonary: respiratory problems</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>cardiovascular: vasospasm</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>other: multi-organ failure, gangrene</td>
</tr>
</tbody>
</table>

**Sources:** 37–40, e20, e21